AVONTEC's lead product AVT-01 advances into multiple-dosing Phase 2a studies in asthma
Novel decoy technology makes transcription factor target drugable
15-Nov-2006 -
AVONTEC´s asthma drug candidate AVT-01 has entered a multiple dosing phase 2a clinical study in the United Kingdom and Romania. Last week, the English regulatory body, the Medicines and Healthcare products Regulatory Agency, and the Romanian regulatory body, the Romanian National Medicines ...
asthma
bases
chronic inflammation
+9